Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.

IF 16.4 1区 化学 Q1 CHEMISTRY, MULTIDISCIPLINARY
Accounts of Chemical Research Pub Date : 2023-07-01 Epub Date: 2023-09-04 DOI:10.2217/pme-2022-0099
Rositsa Koleva-Kolarova, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen Rutten-van Mölken, László Szilberhorn, Tamás Zelei, Balázs Nagy, Sarah Wordsworth, Apostolos Tsiachristas
{"title":"Cost-effectiveness of extended <i>DPYD</i> testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.","authors":"Rositsa Koleva-Kolarova,&nbsp;Heleen Vellekoop,&nbsp;Simone Huygens,&nbsp;Matthijs Versteegh,&nbsp;Maureen Rutten-van Mölken,&nbsp;László Szilberhorn,&nbsp;Tamás Zelei,&nbsp;Balázs Nagy,&nbsp;Sarah Wordsworth,&nbsp;Apostolos Tsiachristas","doi":"10.2217/pme-2022-0099","DOIUrl":null,"url":null,"abstract":"<p><p>The aim of this study was to evaluate the cost-effectiveness of ToxNav<sup>©</sup>, a multivariant genetic test, to screen for <i>DPYD</i> followed by personalized chemotherapy dosing for metastatic breast cancer in the UK compared with no testing followed by standard dose, standard of care. In the main analysis, ToxNav was dominant over standard of care, producing 0.19 additional quality-adjusted life years and savings of £78,000 per patient over a lifetime. The mean additional quality-adjusted life years per person from 1000 simulations was 0.23 savings (95% CI: 0.22-0.24) at £99,000 (95% CI: £95-102,000). Varying input parameters independently by range of 20% was unlikely to change the results in the main analysis. The probabilistic sensitivity analysis showed ~97% probability of the ToxNav strategy to be dominant.</p>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2022-0099","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 2

Abstract

The aim of this study was to evaluate the cost-effectiveness of ToxNav©, a multivariant genetic test, to screen for DPYD followed by personalized chemotherapy dosing for metastatic breast cancer in the UK compared with no testing followed by standard dose, standard of care. In the main analysis, ToxNav was dominant over standard of care, producing 0.19 additional quality-adjusted life years and savings of £78,000 per patient over a lifetime. The mean additional quality-adjusted life years per person from 1000 simulations was 0.23 savings (95% CI: 0.22-0.24) at £99,000 (95% CI: £95-102,000). Varying input parameters independently by range of 20% was unlikely to change the results in the main analysis. The probabilistic sensitivity analysis showed ~97% probability of the ToxNav strategy to be dominant.

英国癌症转移性乳腺癌氟嘧啶化疗前延长DPYD试验的成本效益。
本研究的目的是评估ToxNav©(一种多变量基因测试)的成本效益,以筛选英国转移性乳腺癌症的DPYD,然后进行个性化化疗剂量,与未进行测试,然后进行标准剂量、标准护理相比。在主要分析中,ToxNav在标准护理中占主导地位,为每位患者带来了0.19个额外的质量调整生命年,并在一生中节省了78000英镑。从1000次模拟中,每人平均额外的质量调整寿命为0.23年(95%置信区间:0.22-0.24),为99000英镑(95%置信度:95-102000英镑)。在20%的范围内独立改变输入参数不太可能改变主分析的结果。概率敏感性分析显示ToxNav策略占主导地位的概率约为97%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Accounts of Chemical Research
Accounts of Chemical Research 化学-化学综合
CiteScore
31.40
自引率
1.10%
发文量
312
审稿时长
2 months
期刊介绍: Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信